Zealand Pharma A/S

Zealand Pharma A/S is a biotechnology company focused on developing innovative peptide-based medicines. Here are key details about the company:

Business Overview

Zealand Pharma specializes in the discovery, development, and commercialization of peptide-based drugs. The company's main focus areas include:

• Diabetes
• Obesity
• Rare diseases

As of 2022, Zealand Pharma had a portfolio of 7 products in clinical development, including 2 in Phase III trials, 3 in Phase II, and 2 in Phase I. They also had 4 products in preclinical development.

Key Products and Pipeline

Some of Zealand Pharma's notable products and drug candidates include:

• Glepaglutide: In development for short bowel syndrome
• Dasiglucagon: For congenital hyperinsulinism and artificial pancreas systems
• Survodutide: For treating obesity and nonalcoholic steatohepatitis
• Dapiglutide: A dual GLP-1/GLP-2 receptor agonist for weight management

Recent Developments

In September 2024, Zealand Pharma announced positive topline results from a Phase 1b trial of dapiglutide for weight management. Key findings included:

• Up to 8.3% reduction in body weight compared to placebo after 13 weekly doses
• Mean weight loss of up to 6.2% in treated participants
• The drug was found to be safe and well-tolerated

The company plans to initiate a comprehensive Phase 2b trial for dapiglutide in the first half of 2025.

Financial Information

As of September 2024:

• Market capitalization: 61.89 billion DKK
• Revenue growth: Over 301% in the last twelve months (as of Q2 2024)
• The company is currently operating at a loss, with negative gross profit and operating income margins

Company Details

• Headquarters: Soborg, Denmark
• Founded: 1998
• Number of employees: 288 (as of 2022)
• CEO: Adam Sinding Steensberg

Zealand Pharma is publicly traded on the Nasdaq Copenhagen stock exchange under the ticker ZEAL.

Based on the search results, here are some key points about Zealand Pharma A/S's current valuation:

1. Market Capitalization: As of September 2024, Zealand Pharma's market capitalization is approximately 61.89 billion DKK (Danish Kroner).
2. Revenue Growth: The company has seen significant revenue growth, with over 301% increase in the last twelve months as of Q2 2024.
3. Profitability: Despite strong revenue growth, Zealand Pharma is currently operating at a loss, with negative gross profit and operating income margins.
4. P/E Ratio: The company has a negative P/E ratio of -72.72, which may indicate expectations of future earnings or that the stock is currently overvalued.
5. Analyst Consensus: The mean consensus among analysts is "OUTPERFORM" with an average target price of 1,015.14 DKK.
6. Price Targets:
   • Average target price: 1,015.14 DKK
   • High price target: 1,106.00 DKK
   • Low price target: 800.00 DKK
7. Future Projections:
   • Forecasted annual revenue for 2030: 5,987 million DKK
   • Forecasted annual EBITDA for 2028: 348 million DKK
8. Recent Stock Performance: As of September 2024, the stock price has seen a significant increase of +137.54% year-to-date.
9. Valuation Metrics:
   • EV / Sales 2024 (estimated): 115x
   • EV / Sales 2025 (estimated): 52.9x
10. InvestingPro Fair Value: The estimated fair value is $73.79, which is below the previous close price of $122.51, potentially indicating the stock might be overpriced according to some analytical models.

It's important to note that while Zealand Pharma has shown strong revenue growth and has promising drug candidates in its pipeline, it is still operating at a loss. The high valuation metrics and negative P/E ratio suggest that investors are pricing in significant future growth potential.